List of Excipients in Branded Drug BETAXOLOL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	BENZALKONIUM CHLORIDE
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	EDETATE DISODIUM
Sandoz Inc	BETAXOLOL HYDROCHLORIDE	betaxolol hydrochloride	61314-245	HYDROCHLORIC ACID

Generic Drugs Containing BETAXOLOL

Company	Ingredient	NDC	Excipient
Marlex Pharmaceuticals Inc	betaxolol	10135-623	ANHYDROUS LACTOSE
Marlex Pharmaceuticals Inc	betaxolol	10135-623	CARNAUBA WAX
Marlex Pharmaceuticals Inc	betaxolol	10135-623	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in BETAXOLOL?

# Of NDCs	Excipient
5	ANHYDROUS LACTOSE
1	BENZALKONIUM CHLORIDE
4	CARNAUBA WAX

Betaxolol Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Betaxolol is a mature beta-1 adrenergic blocker with limited active-ingredient exclusivity and established oral and ophthalmic dosage forms. The strongest commercial opportunities are in ophthalmic delivery: preservative-free multidose systems, lower-irritancy formulations, suspension-to-solution conversion, improved ocular residence time, and combination products. Excipient selection can create regulatory and differentiation advantages, but formulation claims must address known prior art and demonstrate meaningful clinical or performance benefits.

What dosage forms and excipients are used for betaxolol?

Betaxolol is marketed primarily as betaxolol hydrochloride in oral tablets and ophthalmic products. Ophthalmic products are used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Oral betaxolol has been used as a systemic beta blocker for hypertension, although its commercial importance is lower than that of other beta blockers.

Dosage form	Typical strength	Principal formulation issue	Commercial relevance
Ophthalmic solution	0.5% betaxolol hydrochloride	Preservative exposure, ocular comfort, stability	Generic and branded competition
Ophthalmic suspension	0.25% betaxolol hydrochloride	Uniform dosing, redispersibility, viscosity	Differentiated branded product opportunity
Immediate-release tablet	10 mg or 20 mg	Dose flexibility, tablet manufacturability	Mature, price-sensitive market
Combination ophthalmic product	Product-dependent	Compatibility with second active ingredient	Potential lifecycle-management opportunity
Preservative-free ophthalmic product	Typically equivalent concentration	Container-closure and microbiological control	Higher-value niche for chronic therapy

The marketed 0.5% ophthalmic solution uses conventional aqueous excipients, including tonicity agents, pH adjusters, chelating agents, and a preservative. The 0.25% suspension uses viscosity- and suspension-control excipients to maintain drug uniformity and ocular residence time. Exact inactive ingredients vary by manufacturer and product label.[1,2]

Which excipient functions matter most?

The key excipient functions for betaxolol ophthalmic products are:

1. Solubilization and pH control.
2. Isotonicity adjustment.
3. Suspension stabilization.
4. Viscosity control.
5. Preservation or microbiological protection.
6. Ocular comfort.
7. Container compatibility.
8. Drop-size and dose-delivery control.

Betaxolol hydrochloride is water-soluble enough for an ophthalmic solution at established concentrations. Commercial value therefore depends less on basic solubilization and more on tolerability, preservative reduction, residence time, delivery consistency, and product usability.

What excipient strategy is appropriate for betaxolol ophthalmic solutions?

A conventional betaxolol solution should use a low-complexity excipient system unless a new formulation provides a measurable advantage. The baseline design normally includes:

Function	Candidate excipient classes	Development objective
Tonicity	Sodium chloride, mannitol, glycerol	Match ocular comfort and osmolality
Buffering	Phosphate, borate, citrate systems	Maintain pH and chemical stability
Chelation	Edetate disodium	Support preservative performance and reduce metal-catalyzed degradation
Preservation	Benzalkonium chloride or alternative systems	Meet antimicrobial preservation requirements
Viscosity	Hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers	Extend residence time without excessive blur
pH adjustment	Hydrochloric acid, sodium hydroxide	Control solubility, comfort, and stability
Surfactant or wetting aid	Product-specific nonionic systems	Improve wetting or suspension uniformity

The established 0.5% solution format creates a high regulatory hurdle for an ordinary generic formulation. A new product needs either lower manufacturing cost, improved tolerability, better adherence, or a clinically meaningful delivery advantage.

How can preservative-free betaxolol create commercial value?

Preservative-free betaxolol is the clearest excipient-led opportunity. Benzalkonium chloride can cause ocular-surface irritation and may be problematic for patients with chronic exposure, ocular-surface disease, or frequent topical treatment. The commercial opportunity is strongest where patients use multiple preserved glaucoma products.

Possible approaches include:

• Unit-dose containers.
• Multidose bottles with antimicrobial container systems.
• Preservative-free valve or pump delivery.
• Sterile blow-fill-seal packaging.
• Alternative antimicrobial systems with reduced ocular-surface burden.
• Low-dose preservative formulations supported by validated microbiological testing.

The principal barrier is container-closure performance. A preservative-free multidose product must control microbial ingress through the package rather than relying on the formulation. That shifts development cost from excipient selection to device qualification, extractables and leachables testing, sterility assurance, in-use stability, and human-factors validation.

A preservative-free formulation can support patent claims directed to the composition, container, dispensing system, and method of treating ocular hypertension. The formulation itself must show a defensible distinction over existing preservative-free beta-blocker products and known ophthalmic delivery systems.

What formulation patents could protect betaxolol products?

Betaxolol’s original active-ingredient exclusivity is historical. Commercial protection today is more likely to come from formulation, container, process, or method-of-use claims than from a new-molecule patent.

Potential claim categories include:

Ophthalmic solution patents

A solution patent could cover:

• A defined pH and osmolality range.
• A specific buffer and chelator combination.
• Reduced preservative concentration.
• Improved chemical stability.
• Lower degradation-product formation.
• A defined viscosity range.
• A specific multidose container.

A narrow composition patent is vulnerable if the claimed excipients are routine choices and the result is predictable. Stronger claims require comparative evidence showing a non-obvious benefit, such as improved stability at elevated temperature, lower ocular irritation, or improved delivered-dose uniformity.

Ophthalmic suspension patents

Suspension claims may cover:

• Particle-size distribution.
• Sedimentation rate.
• Redispersibility after storage.
• Polymer concentration.
• Suspension rheology.
• Uniformity across the bottle life.
• Reduced shaking requirement.
• Drop-size consistency.

Betaxolol suspension products have a technical advantage over simple solutions only if they offer a recognized clinical or usability benefit. Excessive viscosity can create blurred vision, inconsistent drop formation, or poor patient acceptance.

Container and delivery-system patents

The package can provide a more defensible commercial moat than the excipient blend. Relevant claim areas include:

• Preservative-free multidose dispensing.
• One-way valves.
• Metered-dose pumps.
• Airless containers.
• Low-retention dropper systems.
• Dose counters.
• Systems that prevent backflow or microbial ingress.
• Packaging that limits sorption or drug loss.

These claims may support premium pricing even when the formulation uses familiar excipients.

Method-of-use patents

Potential method-of-use claims include:

• Treatment of ocular hypertension in patients intolerant to benzalkonium chloride.
• Reduced dosing frequency through enhanced ocular retention.
• Use in patients with ocular-surface disease.
• Combination therapy with prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-2 agonists.
• Specific dosing regimens designed to reduce systemic beta-blocker exposure.

Method-of-use protection is commercially useful only when the label supports the claimed population or regimen. Generic applicants may challenge such claims through a Paragraph IV certification or use a section viii statement that omits the patented indication, depending on the Orange Book listing and claim scope.[3]

When does betaxolol lose exclusivity, and what is the Orange Book status?

Betaxolol is a legacy active ingredient. The principal compound and early dosage-form patents have expired or are no longer the primary commercial barrier in the United States. The market is therefore generally characterized by generic competition rather than new-chemical-entity exclusivity.

Regulatory issue	Betaxolol implication
New chemical entity exclusivity	Historical and expired
Basic compound patent	Historical and generally expired
Current market barrier	Product-specific formulation, device, manufacturing, or method claims
Paragraph IV exposure	Relevant only where an unexpired listed patent covers an approved reference product
Orange Book relevance	Depends on the specific reference-listed drug and currently listed patents
Biosimilar pathway	Not applicable; betaxolol is a small molecule
Generic pathway	Abbreviated New Drug Application pathway is the principal route

The Orange Book must be reviewed at the product level because listed patents, marketing status, and reference-listed-drug designations can change. A betaxolol product cannot be assigned a reliable patent-expiration date solely from the active ingredient name.[3]

Which companies are challenging betaxolol patents?

Betaxolol is not generally viewed as a current high-value Paragraph IV battleground comparable with recently approved branded medicines. Generic competition has historically involved multiple manufacturers, and the principal commercial issue is product approval, supply economics, and substitution rather than an active patent dispute.

Any current litigation assessment must distinguish among:

• Betaxolol hydrochloride tablets.
• 0.5% ophthalmic solution products.
• 0.25% ophthalmic suspension products.
• Combination ophthalmic products.
• Device-enabled or preservative-free products.

A company developing a new betaxolol formulation should conduct a current USPTO, FDA Orange Book, and federal-court review before filing. Historical expired patents do not establish freedom to operate for a modern container, polymer system, or combination product.

How strong is the patent estate for betaxolol?

The baseline patent estate is weak for the active ingredient and stronger only for narrowly defined product improvements.

Asset type	Relative strength	Reason
Betaxolol molecule	Low	Mature active ingredient
Conventional tablet excipients	Low	Routine generic formulation territory
Conventional ophthalmic solution	Low to moderate	Many predictable excipient options
Preservative-free multidose system	Moderate to strong	Device and microbiological-control complexity
Novel suspension rheology	Moderate	Requires demonstrated performance advantage
Combination ophthalmic product	Moderate	Depends on compatibility, clinical rationale, and prior art
Manufacturing process	Moderate	Stronger when it solves stability, sterility, or uniformity problems
Method of use	Variable	Depends on claim specificity and label support

The most defensible strategy is to combine composition, device, process, and use claims. A single narrow excipient claim is easier to design around.

What manufacturing and regulatory barriers affect betaxolol formulations?

FDA approval requires more than demonstration of chemical identity. Ophthalmic betaxolol products must address sterility, particulate matter, visible inspection, preservative effectiveness where applicable, extractables and leachables, container compatibility, stability, and delivered-dose performance.[4,5]

Key technical barriers

A development program should evaluate:

• Assay and degradation products.
• pH drift during storage.
• Osmolality.
• Viscosity and rheology.
• Particle-size distribution for suspensions.
• Shake uniformity.
• Dose uniformity throughout container use.
• Drop size and actuation force.
• Microbial limits and sterility.
• Preservative effectiveness.
• In-use stability.
• Sorption to plastic components.
• Interaction between polymers and the active ingredient.

The FDA ophthalmic product guidance places substantial importance on sterility and packaging controls. A formulation that is chemically stable in a laboratory vial may fail in the commercial container because of adsorption, evaporation, extractables, or microbial ingress.[4]

Can excipients create bioequivalence advantages?

For an ophthalmic generic, excipients can affect local bioavailability, residence time, viscosity, drop size, and irritation. A formulation that differs materially from the reference product may require comparative performance evidence beyond conventional pharmaceutical equivalence.

Potential advantage areas include:

• Equivalent intraocular pressure reduction with lower administered volume.
• Comparable exposure with reduced preservative burden.
• Improved retention through controlled viscosity.
• More consistent dosing from the first to the last drop.
• Reduced shaking requirements for suspensions.
• Improved patient tolerability.

The commercial objective should be a clinically relevant product profile, not simply a more complex excipient list.

What commercial opportunities exist for betaxolol?

Preservative-free chronic-use products

Patients with glaucoma often use topical therapy for years. A preservative-free betaxolol product could target patients with ocular-surface disease, contact-lens use, postoperative sensitivity, or intolerance to preserved products.

The main commercial risks are packaging cost, reimbursement limits, and competition from preservative-free prostaglandin analogues and fixed combinations.

Improved suspension products

A redesigned 0.25% suspension could compete on:

• Faster redispersion.
• Less vigorous shaking.
• Lower residue.
• Better drop uniformity.
• Reduced transient visual disturbance.
• Longer in-use stability.

The product would need a clear advantage over both the reference suspension and generic solution alternatives.

Fixed-dose combinations

Betaxolol may be paired with another intraocular-pressure-lowering agent, such as a carbonic anhydrase inhibitor or alpha-2 agonist. Combination development can reduce dosing burden, but clinical and commercial competition is intense. Prostaglandin-based combinations generally have stronger prescribing momentum.

Combination products also create compatibility challenges, including pH differences, preservative requirements, precipitation risk, and stability interactions. A successful product would need a strong adherence or tolerability rationale.

Device-enabled delivery

A metered-dose or low-waste system could reduce administration variability and improve the patient experience. Device differentiation may support premium pricing where the formulation is otherwise commoditized.

Potential value drivers include:

• Accurate delivery for patients with limited dexterity.
• Reduced bottle contamination.
• Lower residual volume.
• Easier administration for older patients.
• Preservative-free multidose use.
• Integrated dose counting.

Emerging-market and hospital opportunities

Betaxolol is inexpensive and widely understood by regulators. A robust, low-cost ophthalmic product may have commercial potential in markets where branded glaucoma combinations are less accessible. The opportunity depends on local registration requirements, tender pricing, preservative preferences, and availability of suitable sterile manufacturing capacity.

How does betaxolol compare with competing glaucoma drugs?

Product class	Betaxolol position	Excipient opportunity
Prostaglandin analogues	Usually stronger efficacy and once-daily positioning	Preservative-free delivery and low-irritancy systems
Nonselective beta blockers	Similar class economics, broader pulmonary limitations	Beta-1 selectivity and tolerability positioning
Carbonic anhydrase inhibitors	Often used in combination therapy	Compatibility and fixed-dose products
Alpha-2 agonists	Useful combination class but tolerability concerns	Reduced preservative burden and comfort
Rho kinase inhibitors	Newer, differentiated mechanisms	Betaxolol competes mainly on cost and familiarity
Fixed combinations	Lower dosing burden	Combination stability and device claims

Betaxolol’s principal clinical differentiation is beta-1 selectivity relative to nonselective beta blockers. Its commercial weakness is the availability of more potent once-daily glaucoma therapies. Excipient innovation must therefore address tolerability, adherence, convenience, and cost rather than rely on mechanism alone.

What revenue exposure and launch scenarios apply to betaxolol?

Betaxolol revenue is exposed to generic erosion, reimbursement substitution, and competition from newer glaucoma therapies. A conventional generic solution is likely to be a low-margin product. A differentiated product can support better economics if it obtains one or more of the following:

• A proprietary device.
• A preservative-free label.
• Improved tolerability evidence.
• A clear dosing-convenience benefit.
• A combination-product approval.
• Strong supply reliability.
• Geographic registration in markets with limited competition.

Launch scenario	Expected positioning	Main risk
Conventional generic solution	Lowest-cost substitution	Price erosion
Improved suspension	Differentiated ophthalmic product	Limited clinical differentiation
Preservative-free unit dose	Chronic-use and sensitive-eye segment	Packaging and manufacturing cost
Preservative-free multidose	Premium convenience product	Device and sterility complexity
Fixed-dose combination	Adherence-focused product	Clinical and competitive intensity
Emerging-market supply product	Tender and access strategy	Low prices and local competition

What is the recommended betaxolol excipient strategy?

The most commercially credible strategy is a preservative-free ophthalmic platform with a validated multidose container, moderate viscosity, controlled drop size, and documented ocular-surface tolerability. The formulation should avoid unnecessary excipient complexity and focus on measurable performance advantages.

A development program should prioritize:

1. Preservative-free multidose feasibility.
2. Comparative ocular comfort.
3. In-use microbiological protection.
4. Container compatibility.
5. Drop uniformity through bottle life.
6. Stability under global climatic conditions.
7. Freedom-to-operate review for formulation and device claims.
8. A patent portfolio covering composition, container, process, and use.

The tablet market offers limited excipient-led upside unless the product targets a specific manufacturing, dose-flexibility, or supply-chain problem. Ophthalmic delivery provides the better platform for product differentiation and licensing.

Key Takeaways

• Betaxolol is a mature small-molecule beta blocker with limited active-ingredient exclusivity.
• Ophthalmic products offer greater excipient-led commercial potential than tablets.
• Preservative-free multidose delivery is the strongest opportunity.
• Suspension rheology, dose uniformity, and redispersibility can support differentiated products.
• Conventional excipient combinations are unlikely to provide strong patent protection without comparative performance data.
• Container and delivery-system claims may be more valuable than composition claims.
• Betaxolol is not subject to biosimilar competition because it is a small molecule.
• Paragraph IV risk depends on the specific reference-listed product and currently listed patents.
• The most attractive launch strategy combines a tolerability benefit with a proprietary sterile delivery system.
• Generic products should be evaluated on supply economics, reimbursement, and manufacturing reliability as much as on formulation.

FAQs

Is betaxolol suitable for a preservative-free ophthalmic product?

Yes. Chronic ophthalmic use creates a rationale for reducing benzalkonium chloride exposure. The central technical challenge is protecting the multidose container from microbial contamination without relying on conventional preservatives.

Which excipients can improve betaxolol eye-drop retention?

Viscosity modifiers such as cellulose derivatives or carbomer-type polymers can increase residence time. The formulation must balance retention against blurred vision, poor drop formation, irritation, and dose nonuniformity.

Can a betaxolol suspension be patented today?

A suspension may be patentable if it has a novel and non-obvious composition or performance profile. Claims based only on routine polymers, tonicity agents, or pH adjusters are more vulnerable to prior-art challenges.

Does betaxolol have biosimilar competition?

No. Betaxolol is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than the biosimilar framework.

What is the best licensing asset in a betaxolol program?

A validated preservative-free multidose ophthalmic platform is likely to have greater licensing value than a conventional betaxolol formulation. The strongest asset would combine formulation data, device protection, sterility performance, and a differentiated tolerability profile.

References

1. U.S. Food and Drug Administration. (2023). Betoptic S (betaxolol hydrochloride ophthalmic suspension) prescribing information.
2. U.S. Food and Drug Administration. (2023). Betaxolol hydrochloride ophthalmic solution prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2008). Guidance for industry: Container closure systems for packaging human drugs and biologics.
5. U.S. Food and Drug Administration. (2023). Guidance for industry: Quality considerations for ophthalmic drug products.
6. United States Pharmacopeia. (2024). USP–NF general chapters for ophthalmic products, sterility, antimicrobial effectiveness, and particulate matter. USP Convention.